Lenvakast — Lenvatinib 4 mg

Indicated for the treatment of:

• Differentiated Thyroid Cancer (DTC): Radioiodine-refractory cases.
• Hepatocellular Carcinoma (HCC): First-line treatment for unresectable liver cancer.
• Renal Cell Carcinoma (RCC): In combination with Everolimus for advanced kidney cancer.

Strength: 4 mg per capsule.

Common Daily Regimens:

• Thyroid Cancer (24 mg): Take 6 capsules once daily.
• Liver Cancer (Body weight ≥ 60 kg): 12 mg (3 capsules) once daily.
• Liver Cancer (Body weight < 60 kg): 8 mg (2 capsules) once daily.

⚠️ Instructions: Take once daily at the same time, with or without food. Swallow whole; do not open, crush, or chew.

• Uncontrolled Hypertension (High Blood Pressure).
• Severe hepatic impairment (Child-Pugh C) or renal failure.
• History of Fistula or Gastrointestinal Perforation.
• Pregnancy and breastfeeding.

Hypertension is the most common adverse reaction. Blood pressure should be well-controlled prior to treatment and monitored regularly.

Other side effects:

• Proteinuria: Protein in urine (requires regular testing).
• Diarrhea and fatigue.
• Palmar-plantar erythrodysesthesia: Hand-foot syndrome (redness/peeling of skin).